Granules India gets approval for Acetaminophen, Aspirin and Caffeine Tablets

24 Feb 2021 Evaluate

Granules India has received approval from the US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC). It is bioequivalent to the reference listed drug product (RLD), Excedrin Migraine Tablets, 250 mg/250 mg/65 mg, of GlaxoSmithKline Consumer Healthcare. The product would be manufactured at Hyderabad facility and is expected to be launched shortly.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

578.30 13.35 (2.36%)
27-Jan-2026 14:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1629.00
Dr. Reddys Lab 1234.70
Cipla 1311.25
Zydus Lifesciences 887.95
Lupin 2129.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×